• Home
  • About APS
  • APS News
  • Job Postings and Ads
  • Events and Education
  • Goverment Affairs
  • 2024 Annual Meeting
  • Education-OUD
  • Education-On Demand
  • Mental Health Resources

To Buy Abilify Online Visit Our Pharmacy ↓

Click HERE To Buy Abilify Online ↓




  • Abilify: a Comprehensive Guide for New Users

    Understanding Abilify: What It Is and How It Works


    Abilify, known generically as aripiprazole, is a versatile antipsychotic medication primarily used to treat conditions like schizophrenia, bipolar disorder, and major depressive disorder adjunctively. By acting as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors while antagonizing serotonin 5-HT2A receptors, Abilify stabilizes mood and reduces the hallucinatory and delusional symptoms often experienced in psychotic disorders. This unique mechanism helps balance the neurotransmitter pathways implicated in these conditions, offering both therapeutic stability and symptom relief.

    Mechanism Description
    Dopamine D2 Partial Agonism Reduces excess dopamine activity, alleviating manic and psychotic symptoms.
    Serotonin 5-HT1A Partial Agonism Enhances mood stabilization and anxiety reduction.
    Serotonin 5-HT2A Antagonism Improves mood and decreases depressive symptoms.

    By harnessing this tri-phasic action, Abilify provides a managed approach to modulating neurological responses, setting it apart from traditional antipsychotic treatments.



    Key Benefits and Uses of Abilify for Patients



    Abilify, a versatile medication, is primarily used to treat mental health conditions such as schizophrenia, bipolar disorder, and in some cases, major depressive disorder. By modulating the activity of certain neurotransmitters in the brain, it helps stabilize mood and alleviate symptoms of these disorders. This makes it a valuable ally for many patients seeking a path to mental well-being.

    Beyond its core uses, Abilify offers benefits like reduced agitation and enhanced cognitive functioning for some individuals. Patients often report improvements in overall quality of life, thanks to its ability to reduce episodes of mania and mood swings. This contribution to emotional stability is crucial in managing day-to-day activities more effectively.

    Moreover, Abilify can be used as an adjunct therapy, meaning it can complement other antidepressants to treat depression more effectively. By doing so, it provides a broader scope of relief for those who struggle with treatment-resistant depression. As patients embark on this medication journey, they often find Abilify to be a key component in their long-term treatment strategy, helping foster hope and balance.



    Common Side Effects and Mitigation Strategies


    Many users of Abilify report experiencing common side effects like insomnia, dizziness, and nausea. These are often mild but can be concerning for those new to the medication. It’s crucial to monitor how your body responds, especially during the initial weeks of treatment. Staying hydrated and maintaining a consistent sleep schedule can alleviate some discomfort. Additionally, consulting with a healthcare provider can help in tailoring a strategy that includes adjustments in lifestyle or minor alterations in dosage to minimize these effects.

    Embracing a proactive approach can be empowering. Sometimes, side effects diminish as the body adjusts over time, but maintaining open communication with your healthcare provider is key. They might recommend changes in how and when you take Abilify or prescribe ancillary treatments to ease any troublesome symptoms, ensuring a smoother experience as you continue with your treatment plan.



    Proper Dosage and Administration Guidelines



    When starting Abilify, it’s crucial to follow your healthcare provider's dosage instructions meticulously. Typically, treatment begins with a lower dose, which may be gradually increased based on your body's response. Abilify is often taken once daily, with or without food, making it easy to incorporate into your routine. It’s essential not to adjust your dose without consulting your doctor, as doing so can affect efficacy and safety. Regular monitoring by your physician will ensure you’re receiving the optimal therapeutic benefits.



    Interactions with Other Medications to Consider


    When it comes to juggling multiple medications, understanding potential interactions with Abilify is crucial for new users. Abilify can interact with a variety of other drugs, affecting how well it works or increasing the risk of side effects. For instance, medications like antihypertensives, such as doxazosin, can amplify the blood pressure-lowering effects of Abilify, leading to dizziness or fainting. Moreover, combining Abilify with other antipsychotics or mood stabilizers may intensify sedative effects, impacting alertness.

    Medication Type Possible Interaction
    Antihypertensives Increased dizziness
    Other Antipsychotics Enhanced sedation

    Patients using Abilify should also be cautious when taking antidepressants or antifungal agents, like ketoconazole. These can raise Abilify levels in the bloodstream, potentially intensifying both beneficial effects and side effects. Always consult healthcare professionals to optimize therapy and minimize risks. Being informed ensures Abilify serves its purpose safely within a treatment plan.



    Real-life Experiences: What New Users Should Know


    Starting a new medication can be daunting, but hearing from others who have walked the same path can ease the journey. Many new users of Abilify share their initial apprehensions and the surprises they encountered. For some, the first few weeks may bring an unexpected boost in energy, helping them rediscover a zest for daily activities. Others might experience a smoother emotional landscape, finding it easier to navigate the ups and downs of life.

    However, it's also common to face challenges. A frequent experience is the need for patience, as the full effects of Abilify often take several weeks to manifest. New users often highlight the importance of open communication with healthcare providers. By sharing experiences and side effects, adjustments can be made, ensuring the medication fits their unique needs and lifestyle effectively.





ARIZONA PSYCHIATRIC SOCIETY 2024-2025 EXECUTIVE Board

President: Nicholas Ahrendt, MD President-Elect: Margaret Balfour, MD, PhDVice President: Brenner Freeman, MDTreasurer: Robert Rymowicz, DOSecretary: Chiranjir "Ravi" Narine, MD Co Resident-Fellow Member Representatives: Nehal Samra, MD Creighton Matthew Mitchell, MD UA-PhoenixGagan Singh, MD UA-Tucson
APA Assembly Representatives: Jason Curry, DO (serves term concluding 2024) Jasleen Chhatwal, MBBS, MD (two-year term concluding 2024)Payam Sadr, MD (one-year term concluding 2024) Past President Gagandeep Singh, MD, DFAPA Stephen "Larry" Mecham, DO The Society thanks these members for their leadership.

Celebrating our members

Chase was born and raised in Phoenix, AZ, and attended ASU for a bachelor’s degree in business then attended KCUMB for medical school in Kansas City. He was excited to return home to AZ when he found out he'd been matched with UACOM – Phoenix for his psychiatry residency.
He was first drawn to the field of psychiatry during his years in medical school as he found the psychiatric subject matter and the patients to be the most engaging and interesting of all his studies. He quickly came to realize that without a healthy mind, one is unable to thoroughly experience life constructive way. He wanted to be the person to help those struggling with mental illness as he found these cases and experiences to be the most rewarding in medicine.
Dr. Crookham said he has been lucky enough to have been matched at a great psychiatric residency program where he gets to learn from great mentors and colleagues every day. He believes his passion for psychiatry along with the relationships he's developed with his colleagues and mentors will carry him to be a lifelong learner and devoted psychiatrist for his future patients.
Meghan is a graduate of Lincoln Memorial University, DeBusk College of Osteopathic Medicine.
She received her Bachelor of Arts from the University of Denver in French and Biology with a concentration in Cognitive Neuroscience.
She is currently a chief resident at UACOM-Tucson in her final year of psychiatry training and will be starting a fellowship in Addiction Medicine at the University of Arizona, Tucson in July.
Her professional interests include physician mental health, adult consult liaison and addiction psychiatry.
In her personal time, she enjoys home design projects, spending time with family, learning about plants, and exploring new places.
Dr. Hintze is currently honeymooning in Japan! Congratulations!!
Danny is originally from Phoenix. Graduated from Brophy, ASU, and UA Tucson Medical School. His background is in economics, philosophy of science, and rational decision-making.
He was drawn to psychiatry because of the conceptual complexity and the profound impact even relatively simple pharmaceutical, medical, and psychotherapeutic interventions can have to empower patients and their families.
As a mentor, he wanted to recognize the many people within the Arizona Medical Community, particularly at UA Tucson, Valleywise, and within organized medicine who have worked to protect and promote medicine as a joyful, compassionate, and healing experience for patients and for all of us who help care for them.

ARIZONA PSYCHIATRIC SOCIETY past presidents

Otto L. Bendheim, M.D. 1960-1961Warren S. Williams, M.D. 1961-1963T. Richard Gregory, M.D. 1963-1964Boris Zemsky, M.D. 1964-1965 Hal J. Breen, M.D. 1965-1966Joseph M. Green, M.D. 1966-1967Irene M. Josselyn, M.D. 1967-1968Hubert R. Estes, M.D. 1968-1969Richard H. Bruner, M.D. 1969-1970Thomas F. Kruchek, M.D. 1970-1971David S. Burgoyne Sr., M.D. 1971-1972Marshall W. Jones, M.D. 1972-1973Harold D. Haeussler, M.D. 1973-1974William B. Haeussler, M.D. 1974-1975Edward S. Gelardin, M.D. 1975-1976Hugo L. Cozzi, M.D. 1976-1977Robert F. Meyer, M.D. 1977-1978James E. Campbell, M.D. 1978-1979Stuart M. Gould, M.D. 1979-1980Elliot M. Heiman, M.D. 1980-1981Stephen V. Shanfield, M.D. 1981-1982Jerry A. Biggs, M.D. 1982-1983Robert C. Shapiro, M.D. 1983-1984Dennis C. Westin, M.D. 1984-1985John H. Jarvis, M.D. 1985-1986James G. Hill, M.D. 1986-1987Robert P. Bevan, M.D. 1987-1988Eugene J. Kinder, M.D. 1988-1989 James M. Campbell, M.D. 1989-1990David S. Burgoyne II, M.D. 1990-1991
Stuart W. Hollingsworth, M.D. 1991-1992Kevin J. Leehey, M.D. 1992-1993Stephen S. Brockway, M.D. 1993-1994Michael H. Stumpf, M.D. 1994-1995Lauro Amezcua-Patino, M.D. 1995-1996David S. Burgoyne II, M.D. 1997-1998Glenn Lippman, M.D. 1998-1999Lisa Jones, M.D. 1999-2000David J. Coons, M.D. 2000-2001James M. Campbell, M.D. 2001-2002Bradley Johnson, M.D. 2002-2003David W. Leicken, M.D. 2003-2004Thomas N. Crumbley, M.D. 2004-2006Jeffrey L. Schwimmer, M.D., M.P.H. 2006-2007Stephen O. Morris, M.D. 2007-2008Jack L. Potts, M.D. 2008-2009Elizabeth A. Kohlhepp, M.D. 2009-2010Michael E. Brennan, M.D. 2010-2011Gretchen Alexander, M.D. 2011-2012Tariq M. Ghafoor, M.D. 2012-2013Joanna K. Kowalik, M.D., M.P.H., 2013-2014Payam M. Sadr, M.D., 2014-2015Roland Segal, M.D., 2015-2016Gurjot Marwah, M.D., 2016-2017Aaron Wilson, M.D., 2017-2018Mona Amini, M.D., 2018-2019 Don J. Fowls, M.D., 2019-2020 Jasleen Chhatwal, M.B.B.S., M.D., 2020-2022 Stephen Larry Mecham, DO, 2022-2023 Gagandeep Singh, MD, DFAPA 2023-2024
Main Menu
  • Home
  • About APS
  • APS News
  • Job Postings and Ads
  • Events and Education
  • 2023 Annual Meeting
  • Education-OUD
  • Education-On Demand
  • Mental Health Resources
Contact Information
Address: 2401 West Peoria Avenue, Suite 315 Phoenix, Arizona 85029
Phone: 602-909-4388
E-mail: admin@azpsych.org
Social
The Arizona Psychiatric Society is committed to ensuring the accessibility of its website to people with disabilities. If you have trouble accessing any of the Arizona Psychiatric Society's resources, please contact us at admin@azpsych.org for assistance Copyright © 2020 Network Solutions, LLC, A Web.com Company. All rights reserved.

We use cookies to enable essential functionality on our website, and analyze website traffic. By clicking Accept you consent to our use of cookies. Read about how we use cookies.

Your Cookie Settings

We use cookies to enable essential functionality on our website, and analyze website traffic. Read about how we use cookies.

Cookie Categories
Essential

These cookies are strictly necessary to provide you with services available through our websites. You cannot refuse these cookies without impacting how our websites function. You can block or delete them by changing your browser settings, as described under the heading "Managing cookies" in the Privacy and Cookies Policy.

Analytics

These cookies collect information that is used in aggregate form to help us understand how our websites are being used or how effective our marketing campaigns are.